Brie Carter

Taiko said it has closed the attack path exploited during the June 21 bridge attack after independent security experts reviewed its security fixes.

Grayscale head of research Zach Pandl said he hopes Strategy will sell approximately US$3 billion of its Bitcoin (CRYPTO:BTC) holdings to cover most of its cash obligations.

The Albanese Government plans to strengthen Australia’s social media minimum age law by giving the eSafety Commissioner broader information‑gathering powers and doubling the maximum penalty for systematic breaches from $49.5 million to $99 million.

DGR Global (ASX:DGR) is investing A$4,970,296 in Sunstone Metals (ASX:STM) to secure a 10% shareholding and the right to nominate a director to Sunstone’s board while it holds at least 10% of Sunstone’s issued capital.

Ripple said it is seeking to expand the use of XRP (CRYPTO:XRP) across approximately US$16 trillion in annual institutional payments and clearing activity processed through businesses it has acquired.

Publicly traded companies holding Solana (CRYPTO:SOL) as part of their corporate treasuries recorded strong intraday gains last Friday, led by Sol Strategies.

US spot Bitcoin (CRYPTO:BTC) exchange-traded funds (ETFs) recorded US$1.79 billion in net outflows for the week ending 26 June, marking the second-largest weekly redemption since these products launched in January 2024.

• FedEx reported $25 billion in fourth-quarter fiscal 2026 revenue while executing a spin-off of its freight division to consolidate core operations.
• The logistics provider exceeded cost-cutting targets by securing over $1 billion in structural savings and achieving an adjusted earnings per share of $6.60.
• Global transportation firms face mounting pressure to offset mixed profitability trends by heavily reducing capital spending and divesting secondary business units.

(CRYPTO:SOL) surged approximately 9.7% in a single day, driving double-digit intraday gains across multiple stocks tied to Solana Digital Asset Treasuries (DATs) — companies that hold SOL as a primary treasury asset.

Replimune (NASDAQ:REPL) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.